Daniel Sigelman

Daniel W. Sigelman is an attorney in Washington, D.C. During the 1980s, he was counsel to a House subcommittee overseeing drug-safety regulation.

Recent Articles

Dangerous Medicine

T hirteen dangerous prescription drugs have been withdrawn from the market in the last decade -- but not before hundreds of patients died and thousands were injured. Yet no congressional committee has investigated why the U.S. Food and Drug Administration approved these dubious medicines or why they were not withdrawn right away. In fact, just this past May, Congress opted instead to renew the arrangement that's a major source of the problem. For 10 years, drugmakers have provided much of the FDA's own funding by paying "user fees." In exchange, the FDA speeds up its regulatory reviews. If this Faustian bargain was a factor in the recent drug calamities, Congress was not about to find out. Instead, the lawmakers allowed the drug companies and the FDA to decide, in closed-door negotiations, how much the industry would have to pony up this time around and just what concessions it would get from its regulators in return. Then Congress tacked the agreement onto an unstoppable bioterrorism...